Puma Biotechnology, Inc.

PBYINASDAQHealthcare● Active

$6.85

$-0.18(-2.56%)

Market Cap$348661274

P/E Ratio—

52W High$7.9

52W Low$3.03

Avg Volume278K

Open$7.17

Beta1.21

Net Income Financials Revenue

Puma Biotechnology, Inc. (PBYI) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

PBYI · net income · updated Jun 9, 2026

Core profitability metrics

PBYI · net income · margin · TTM · CAGR

Net income was $31.1M for FY2025 (fiscal year ending 2025-12-31), up 2.8% year-over-year. Net profit margin was 13.6%. Based on available data, Puma Biotechnology, Inc. has been profitable since at least 2022.

FY2025 Net Income$31.1M▲ +2.8% YoY

Trailing 12M (TTM)$24.4Mtrailing 4 quarters sum

Net Profit Margin13.6%$31.1M ÷ $228.4M

YoY Change+2.8%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2022

▸ FMP /income-statement · Annual · PBYI net income history · PBYI profit margin

Annual net income data

PBYI · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025$31.1M▲ +2.8%13.6%$228.4M

FY2024$30.3M▲ +40.2%13.1%$230.5M

FY2023$21.6M▲ +1079450.0%9.2%$235.6M

FY2022★ First Profit$2,000▲ +100.0%0.0%$228.0M

FY2021Loss−$29.1M▲ +51.5%-11.5%$253.2M

Net income vs peers (Healthcare)

PBYI vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Puma Biotechnology, Inc.YOU

PBYI

$31.1M+2.8%13.6%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Puma Biotechnology, Inc. (PBYI) reported net income of $31.1M for FY2025 (fiscal year ending 2025-12-31), up 2.8% year-over-year. The net profit margin was 13.6% — meaning the company kept $0.14 of every dollar of revenue as profit.

Based on available data, Puma Biotechnology, Inc. has been profitable since at least 2022. Net income reached a peak of $31.1M in FY2025. Data available for 15 fiscal years.

Puma Biotechnology, Inc.'s net profit margin was 13.6% for FY2025, based on the latest annual results.

Investors sometimes search for "Puma Biotechnology, Inc. net worth" — the company's market capitalization is a separate figure from PBYI net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

PBYI net income · 5 questions

Puma Biotechnology, Inc. is profitable. The company reported net income of $31.1M for FY2025, a net profit margin of 13.6%. Net income was up 2.8% year-over-year. Based on available data, Puma Biotechnology, Inc. has been profitable since at least 2022.

is PBYI profitabledoes PBYI make a profitPBYI profitabilityPBYI profitable company

▸ Source: FMP /income-statement · GAAP · Puma Biotechnology, Inc. · Puma Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026